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Abstract
Thyrotropin (TSH) and pharmacological agents that elevate intracellular cAMP concentrations potentiate the mitogenic
response of FRTL-5 thyroid cells to insulin-like growth factor-I (IGF-I). This study was undertaken to determine the role of
cAMP phosphodiesterases (PDEs) in this TSH-dependent regulation. Incubation of FRTL-5 cells with TSH, forskolin, or
dibutyryl cAMP gradually induced the PDE activity, and treatment for 24 h produced a marked increase in type 4 high
affinity cAMP PDEs. Under basal conditions, transcripts corresponding to PDE4A, PDE4B, PDE4C, and PDE4D were
present. Stimulation for 24 h by TSH, forskolin or dibutyryl cAMP induced an increase in mRNA levels of PDE4B, PDE4D,
and PDE4C. To understand the role of this cAMP-dependent PDE regulation in the potentiation of the mitogenic response
to IGF-I, thymidine incorporation into DNA in response to IGF-I and TSH was measured in the absence or presence of
PDE inhibitors. Exposure of the cells to 3-isobutyl-1-methylxanthine (IBMX) or RO 20-1724 had opposing effects on
thymidine incorporation into DNA, depending on the stimulus applied. When IGF-I was used alone, both IBMX and RO
20-1724 potentiated IGF-I-stimulated thymidine incorporation. However, when IGF-I and TSH at high concentrations were
used in combination, these PDE inhibitors blocked thymidine incorporation into DNA. In addition, these inhibitors
depressed the synergistic increase in cyclin D1 and cyclin D- or cyclin E-associated cyclin-dependent kinase (CDK) activity
that is induced by TSH and IGF-I. Increased CDK activities have been shown to play a crucial role in progression through
the G1/S phase of the cell cycle. These data demonstrate that TSH produces marked changes in the cAMP degradative
pathway of FRTL-5 cells by regulating the expression of cAMP PDEs. The regulation of the intracellular cAMP levels by
this mechanism may contribute to the TSH- and IGF-I-dependent control of the entry into the S phase of the cell cycle
through changes in the cyclin/CDK system in FRTL-5 cells. ß 2001 Elsevier Science B.V. All rights reserved.
0167-4889 / 01 / $ ^ see front matter ß 2001 Elsevier Science B.V. All rights reserved.
PII: S 0 1 6 7 - 4 8 8 9 ( 0 1 ) 0 0 1 1 9 - 7
Abbreviations: cAMP, cyclic adenosine 3P,5P-monophosphate; DNA, deoxynucleic acid; dCTP, deoxycytidine 5P-triphosphate; Tris,
tris(hydroxymethyl)aminomethane; EDTA, ethylenediaminetetraacetic acid; EGTA, ethylene glycol-bis(2-aminoethyl ether)tetraacetic
acid; PMSF, phenylmethanesulfonyl £uoride; KIU, kallikrein-inactivating unit(s) ; HPLC, high performance liquid chromatography;
DEAE, diethylaminoethyl; Bt2cAMP, dibutyryl cAMP; Rb, retinoblastoma protein
* Corresponding author. Present address: address d. Fax: +81-3-58-41-80-38.
E-mail address: atkshin@mail.ecc.u-tokyo.ac.jp (S.-I. Takahashi).
1 Present address: address c.
BBAMCR 14773 17-7-01
Biochimica et Biophysica Acta 1540 (2001) 68^81
www.bba-direct.com
Keywords: cAMP; Thyrotropin; Insulin-like growth factor-I; cAMP phosphodiesterase; Phosphodiesterase inhibitor
1. Introduction
It has been demonstrated both clinically and in a
wide range of cell or tissue preparations from dog,
human and rat thyroid that thyrotropin (TSH) stim-
ulates proliferation of thyroid follicular cells [1]. In
the rat thyroid cell line FRTL-5 [2], mitogenic stim-
ulation is dependent on the continuous presence of
insulin-like growth factor-I (IGF-I) or insulin [4^6].
In this in vitro system, TSH potentiates the respon-
siveness of the cells to IGF-I. It is clear that TSH
stimulation of cell replication, or the potentiation of
the IGF-I e¡ects, can be mimicked by cAMP ana-
logues or forskolin indicating that the TSH regula-
tion of thyroid cell entry into the cell cycle is medi-
ated by the cAMP-dependent pathway [3^6]. The
present study further investigated the role of the
TSH-activated cAMP-dependent pathway in the rep-
lication of FRTL-5 thyroid cells.
The exact role of cAMP in the regulation of the
cell cycle is a matter of considerable controversy,
because cAMP has been reported to both stimulate
and suppress cell replication in di¡erent systems
[7,8]. At present it is not clear whether these con£ict-
ing results are because every cell type responds di¡er-
ently to cAMP in terms of replication, or are due to
subtle di¡erences in experimental conditions. This
latter possibility is supported by experiments carried
out in BALB/c 3T3 ¢broblasts [9,10]. In this cell
model, di¡erences in the concentration of intracellu-
lar cAMP determine the stimulatory or inhibitory
actions of various mitogens on the replication of
these cells [9,10]. A small increase in cAMP for a
limited time is stimulatory of replication while a
large sustained increase is inhibitory. Intracellular
cAMP concentrations are determined by the rate of
its synthesis by adenylate cyclase and its rate of deg-
radation by phosphodiesterases.
Here we have investigated the possibility that TSH
regulates the phosphodiesterase (PDE) activity of
these cells in a long-term fashion and that this regu-
lation plays an important role in the control of intra-
cellular cAMP levels and mitogenic activity.
2. Materials and methods
2.1. Materials
Coon’s modi¢ed Ham’s F-12 medium (Coon’s
F-12) and newborn calf serum were purchased from
Gibco (Grand Island, NY). Bovine insulin and hu-
man transferrin were purchased from Sigma (St.
Louis, MO). Bovine TSH (1.23 units/mg) for culture
was purchased from Armour and puri¢ed bovine
TSH (30 units/mg) for biological studies was a gen-
erous gift from the National Hormone and Pituitary
Program (National Institute of Diabetes and Diges-
tive and Kidney Diseases; NIDDK). Recombinant
human IGF-I was a generous gift from Dr. W.J.
Rutter (Chiron, Emeryville, CA) and Drs. M. Niwa
and T. Okuma (Fujisawa Pharmaceutical Co., Osa-
ka, Japan). Crotalus atrox snake venom was pur-
chased from Sigma. RO 20-1724 was obtained from
Ho¡mann-La Roche (Nutley, NJ), rolipram was
from Berlex (Wayne, NJ), cilostamide was a gener-
ous gift from Dr. H. Hidaka (Nagoya University
School of Medicine, Nagoya, Japan). AG-1-8 was
from Bio-Rad (Richmond, CA). Leupeptin and pep-
statin were kindly donated by Dr. T. Aoyagi (Insti-
tute of Microbial Chemistry, Tokyo, Japan). Labeled
compounds: 2,8-[3H]cAMP (20^50 Ci/mmol) and
[32P]dCTP (3000 Ci/mmol) were purchased from Du-
Pont-New England Nuclear (Boston, MA) and
[methyl-3H]thymidine (6.5 mCi/mmol) and Na125I
(110 Ci/ml) were purchased from Amersham Phar-
macia Biotech (Arlington Heights, IL). Guanidium
thiocyanate was from Sigma (Milwaukee, WI),
CsCl from Gallard and Schlessinger (Carle Place,
NY), Biotrans nylon membrane from ICN (Costa
Mesa, CA), and a random-primed DNA labeling
kit was from Boehringer-Mannheim (Indianapolis,
IN). Anti-cyclin D1 antibody was purchased from
BD Pharmingen (San Diego, CA), anti-cyclin E anti-
body from Santa-Cruz Biotechnology (Santa Cruz,
CA), and anti-p27Kip1 antibody from Transduction
Laboratories (San Diego, CA). Anti-phosphoRb
(S807/S811) antibody was from New England Bio-
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labs (Hertfordshire, UK). All other chemicals were
reagent grade from Sigma.
2.2. Cell cultures
FRTL-5 cells (ATCC No. CRL8350), a line of rat
thyroid follicular cells developed by Ambesi-Impiom-
bato et al. [2], were generously provided by Dr. L.
Kohn (Section of Cell Regulation, NIDDK) and
from the Interthyr Research Foundation (Baltimore,
MD). Cells were routinely cultured in Coon’s F-12
medium supplemented with 5% newborn calf serum
and a mixture of three hormones (3H medium)
that included TSH (1 mU/ml), insulin (10 Wg/ml),
and transferrin (5 Wg/ml). Cells were cultured in
150 cm2 £asks (Corning, Corning, NY) at 37‡C
in an atmosphere of 95% air, 5% CO2 in a hu-
midi¢ed incubator, as described by Takahashi et
al. [5].
FRTL-5 cells of early passages (passage No. 16^
25) were sparsely seeded (8U106 cells/150 cm2 £ask
for RNA extraction, 4U106 cells/100 mm dish for
PDE assay, 5U105 cells/60 mm dish for immunoblot-
ting, 1U105 cells/well of a 24-well plate for cAMP
assay, and 5U104 cells/well of a 48-well plate for
DNA synthesis and iodide uptake assays) in Coon’s
F-12 medium containing 5% newborn calf serum and
3H. Five days later, the cells were washed twice with
Hanks’ balanced salt solution (HBSS) and cultures
were continued for an additional 24 h in Coon’s F-12
medium containing 0.1% bovine serum albumin
(BSA) until the cells became quiescent. The medium
was replaced with Coon’s F-12 medium containing
0.1% BSA with or without test reagents (TSH, dibu-
tyryl cAMP, cholera toxin, and forskolin) for the
times indicated.
2.3. Phosphodiesterase assay
The assays of the phosphodiesterase activity were
performed as previously described [11]. Quiescent
FRTL-5 cells were treated with test reagents for var-
iable times, rinsed twice with phosphate-bu¡ered
saline (PBS), harvested in a homogenization bu¡er
(40 mM Tris^HCl, pH 8.0, 5 mM L-mercaptoetha-
nol, 10 mM NaF, 1 mM EDTA, 0.2 mM EGTA,
2 mM PMSF, 0.5 Wg/ml leupeptin, 0.7 Wg/ml pepsta-
tin, 5 kallikrein-inactivating units (KIU)/ml aproti-
nin, and 10 mg/ml soybean trypsin inhibitor) and
homogenized in an all-glass Dounce homogenizer.
Aliquots of the homogenate were used in the PDE
assay. Conditions of the assay were as previously
reported [12]. Data were corrected for the amount
of protein present in the extracts. Protein content
was measured by the Lowry method as modi¢ed by
Bensadoun and Weinstein [13]. In all experiments,
each point represents the mean þ S.E.M. of three rep-
licate dishes. Experiments were repeated at least
three times.
2.4. HPLC^DEAE ion exchange chromatography of
FRTL-5 extracts
The soluble extracts of FRTL-5 cells treated for
24 h in the absence or presence of TSH were loaded
onto a HPLC^DEAE ion exchange column preequi-
librated with a starting bu¡er (70 mM Na acetate,
pH 6.5, 10 mM NaF, 5 mM L-mercaptoethanol,
1 mM EDTA, and 0.2 mM EGTA). After extensive
washing, bound proteins were eluted with a 30 min
gradient 70^750 mM Na acetate bu¡er [14]. An ali-
quot of each fraction was assayed for PDE activity
using 1 mM cAMP as a substrate. Data were cor-
rected for the amount of protein loaded on the col-
umn.
2.5. RNA extraction and Northern blot analysis
Poly(A) RNA was prepared as previously de-
scribed [15]. RNA was glyoxylated and fractionated
by electrophoresis through a 1% agarose gel, trans-
ferred to Biotrans nylon membranes, and hybrid-
ized with random primed 32P-labeled cDNAs. Hy-
bridization conditions were as previously reported
[15].
2.6. DNA synthesis assay
Assay of DNA synthesis was performed as de-
scribed previously [5]. For studies with [methyl-
3H]thymidine incorporation into DNA, quiescent
FRTL-5 cells on 48-multiwell plates were treated
with or without test agents for the indicated times.
Unless otherwise indicated, [methyl-3H]thymidine
(0.3 mCi/well ; 1 mCi/ml) was added to each well
4 h before the termination of each experiment. The
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labeling was stopped by adding 1 M ascorbic acid
and the medium was aspirated. The cells were
washed twice with ice-cold PBS and twice with ice-
cold 10% trichloroacetic acid (TCA). TCA precipi-
tated material was solubilized with 250 Wl of 0.2 N
NaOH and 0.1% sodium dodecyl sulfate (SDS).
Cell-associated radioactivity was measured in an
LKB liquid scintillation spectrometer (LKB, Rock-
ville, MD) equipped for automatic quench correc-
tion by an external standard. Each experimental
point represents the mean and S.E.M. of triplicate
wells.
2.7. Intracellular cAMP measurements
For measurement of intracellular cAMP concen-
tration, quiescent FRTL-5 cells on 24-multiwell
plates were treated with test reagents for 24 h. After
treatment, cells were immediately washed twice with
ice-cold PBS and intracellular cAMP was extracted
overnight at 4‡C with ethanol containing 0.1% TCA.
The extracts were centrifuged to remove cell debris
and the supernatants lyophilized. The lyophilized
samples were dissolved in 50 mM Na acetate
and aliquots were used for cAMP radioimmuno-
assay (RIA) [16] after suitable acetylation and dilu-
tion [17]. Some of the samples were measured by
cAMP enzyme immunoassay (EIA) kit (Amersham
Pharmacia Biotech). The amount of protein present
in each well was determined by the Lowry method
[18].
2.8. Iodide uptake assay
Iodide uptake was performed according to the
method of Weiss et al. [19]. After 5 days culture in
Coon’s F-12 medium containing 0.1% BSA, quies-
cent cells were incubated for 24 h with the test agent.
After extensive washing, cells were incubated for an
additional hour at 37‡C with 1 mM NaI containing
0.1 mCi Na125I. At the end of the incubation, cells
were washed twice with cold HBSS containing 10
mM EGTA. Intracellular iodide was extracted with
10% TCA and counted in the automated Q-counter.
Nonspeci¢c binding of iodide was determined by
parallel incubation in the presence of 10 mM
NaClO4 and these values were subtracted from the
incorporated counts.
2.9. Immunoblotting analysis of G1 cyclin, cyclin-
dependent kinase inhibitor and phosphoRb
Quiescent FRTL-5 cells on a 60 mm dish were
treated without or with the test agents indicated. Im-
munoblotting of the cell extracts was performed ba-
sically as described previously [20]. Brie£y, the cells
were harvested at 0‡C in 200 Wl of immunoprecipita-
tion bu¡er solution containing 50 mM Tris^HCl pH
8.0, 150 mM NaCl, 10 mM EDTA, 1 mM EGTA,
1.5 mM MgCl2, 1% NP-40, 100 KIU/ml aprotinin,
20 Wg/ml PMSF, 10 Wg/ml leupeptin, and 5 Wg/ml
pepstatin. The lysates were centrifuged at 15 000Ug
for 10 min at 4‡C. The protein assay of the super-
natant was carried out using a protein assay kit (Bio-
Rad, Hercules, CA). Twenty-¢ve microliters of con-
centrated 3ULaemmli’s sample bu¡er solution con-
taining 9% SDS, 15% glycerol, 30 mM Tris^HCl pH
7.8, 0.05% bromophenol blue, 6% 2-mercaptoethanol
were added to 50 Wl of the supernatant, and the
mixture was boiled for 5 min. A fraction of each
sample that contained the same amount of proteins
was run on 12% SDS^PAGE to perform immuno-
blotting using anti-cyclin D1 antibody, anti-cyclin
E antibody, anti-p27Kip1 antibody or anti-phospho-
Rb (S807/S811) antibody as described previously
[20].
2.10. Analysis of cyclin E-associated histone H1
kinase activity
Measurements of the activities of cyclin E-associ-
ated histone H1 kinase activities were performed as
follows. Quiescent FRTL-5 cells were treated for 24
h in 2 ml of Coon’s F-12 medium with 0.1% BSA
without or with the test agents indicated. The cells
were then harvested and the lysates prepared as de-
scribed above. Equal amounts of proteins (500 Wg
protein) of each sample were subjected to immuno-
precipitation using anti-cyclin E antibodies. Cell-free
phosphorylation was initiated by adding the reaction
mixture to give ¢nal concentration of 20 mM
HEPES-NaOH pH 7.4, 40 mM MgCl2, 1% NP-40,
50 WM [Q-32P]ATP (approx. 220 Ci/pmol) and 2 Wg/
ml histone H1. After 30 min incubation at 25‡C, the
reactions were terminated by boiling these samples
with half volume of concentrated 3ULaemmli’s sam-
ple bu¡er solution. Fifteen percent SDS^PAGE were
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performed and incorporated radioactivity into the
substrates was detected by autoradiography.
3. Results
3.1. Regulation of the PDE activity by TSH and
agents that increase cAMP
To test whether TSH produces long-term changes
in the PDE activity of FRTL-5 cells, cAMP hydro-
lytic activity was measured in homogenates of con-
trol cells and cells that had been treated for 24 h with
hormones or other agents known to activate the
cAMP pathway of these cells (Fig. 1). This long-
term TSH incubation produced a 2^3-fold increase
in total PDE activity, while IGF-I had no signi¢cant
e¡ect. Although marked synergism on thymidine in-
corporation into DNA was observed with a com-
bined treatment [5], treatment with TSH plus IGF-I
caused an increase in PDE activity identical to that
produced by TSH alone. The membrane-permeable
cAMP analogue dibutyryl cAMP and the adenylate
cyclase activator forskolin both stimulated the PDE
activity measured in the homogenate, suggesting that
the TSH e¡ects are mediated by an increase in intra-
cellular cAMP concentration.
To follow the time course of TSH stimulation, the
PDE activity was measured at di¡erent intervals
after the hormone addition (data not shown). In
agreement with previous results [21], the PDE activ-
ity increased rapidly between 0 and 2^3 h with no
apparent time lag. This initial phase was followed by
a slower increase between 4 and 18 h. The activity
remained elevated between 18 and 48 h. The ob-
served PDE stimulation occurred at physiological
concentrations of TSH (data not shown), since the
increase in PDE activity was dependent on the TSH
concentration with an EC50 of 10311 M TSH. These
concentrations are comparable to those required for
half-maximal stimulation of thymidine incorporation
into DNA and stimulation of iodide uptake by these
cells (data not shown). Taken together these data
indicate that physiological concentrations of TSH
regulate the PDE activity present in FRTL-5 cells,
and that this regulation is mediated by the activation
of the cAMP-dependent pathway.
3.2. Mechanisms of regulation of the PDE activity
by TSH
To further de¢ne the nature of the phosphodiester-
Table 1
PDE activities in fraction No. 25 in the absence or presence of
various PDE inhibitors
Fraction No. 25
Control TSH
(% of PDE activity without inhibitors)
No inhibitors 100 100
RO 20-1724 (10 WM) 11.1 þ 1.8 8.2 þ 1.2
Rolipram (10 WM) 23.2 þ 2.8 17.1 þ 2.8
Cilostamide (10 WM) 107.9 þ 8.5 95.3 þ 5.8
IBMX (500 WM) 15.3 þ 2.2 15.8 þ 3.3
Fraction No. 25 prepared from control or TSH-treated FRTL-
5 cells was preincubated with the PDE inhibitor indicated for
30 min and PDE assay was then performed as described in Sec-
tion 2. The activity was measured as triplicate and the results
are the mean þ S.E.M. from the triplicate samples. Values are
expressed as a percentage of PDE activity without inhibitors in
fraction No. 25 prepared from control or TSH-treated cells, re-
spectively.
Fig. 1. TSH regulation of total PDE activity in FRTL-5 cell
homogenates. After incubation for 24 h in the absence of hor-
mones or growth factors, cells were stimulated for 24 h with
TSH (1039 M), IGF-I (25 ng/ml), TSH (1039 M) plus IGF-I
(25 ng/ml), dibutyryl cAMP (Bt2cAMP) (1033 M), or forskolin
(1034 M). At the end of the incubation, cells were harvested
and cell extracts prepared as detailed in Section 2. Di¡erent
concentrations of homogenates were assayed for phosphodies-
terase activity using 1 mM cAMP as a substrate. Each bar is
the mean þ S.E.M. of three independent observations.
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ase regulated by long-term TSH treatment, the PDE
activity present in FRTL-5 cells was characterized by
DEAE^ion exchange chromatography. Extracts from
the control and TSH-treated cells were fractionated
on HPLC^DEAE ion exchange chromatography and
the PDE activity was measured in the eluates (Fig.
2). Under these assay conditions, cAMP hydrolytic
activity of the control cells eluted in four peaks with
retention times of 7.5, 20, 22, and 24 min. TSH treat-
ment produced a major increase of activity with a
retention time of 25 min. This increase masked the
activity of the other peaks. An additional peak with
a retention time of 17 min appeared after TSH treat-
ment. This major form present in the cells treated
without or with TSH (fraction No. 25) was sensitive
to PDE inhibitors, RO 20-1724 and rolipram, but
was insensitive to cilostamide (Table 1). On the basis
of the inhibitor sensitivity and a⁄nity for cAMP, the
TSH-regulated form can be classi¢ed as a high a⁄n-
ity cAMP PDE type 4 according to the nomenclature
of Beavo et al. [22].
Fig. 3. Northern blot analysis of the cAMP PDE mRNA levels
in FRTL-5 cells treated with TSH or cAMP-generating agent,
cAMP analogue, and/or IGF-I. (A) After incubation for 24 h
in the absence of hormones or growth factors, cells were incu-
bated for 24 h in the absence or presence of TSH (1039 M),
IGF-I (25 ng/ml), or a combination of the two. At the end of
the incubation, cells were harvested and RNA extracted accord-
ing to the method described in Section 2. Ten micrograms of
poly(A) RNA were loaded on each lane. The ¢lter was hy-
bridized following the conditions reported in Section 2 using a
random primed 32P-cDNA probe corresponding to PDE4A.
After detection of the radioactivity by autoradiography, the
probe was removed as detailed and the ¢lter hybridized with
the other probes. The experiments were performed twice inde-
pendently and a representative blot is shown. (B) After incuba-
tion for 24 h in the absence of hormones or growth factors,
cells were treated for 24 h in the absence or presence of either
TSH (1039 M), dibutyryl cAMP (1033 M), or forskolin (1034
M). After incubation, cells were harvested and the cAMP PDE
mRNA levels were measured by Northern blot analysis as de-
tailed. Five micrograms of poly(A) RNA were loaded on each
lane. The experiments were performed three times independently
and a representative blot is shown.
Fig. 2. Measurement of the PDE activity fractionated by
HPLC^DEAE ion exchange chromatography of cell extracts
from control and TSH-treated FRTL-5 cells. After incubation
for 24 h in the absence of hormones or growth factors, cells
were incubated for 24 h in the presence or absence of TSH
(1039 M). At the end of the incubation, cells were harvested
and the soluble fraction was prepared as detailed in Section 2.
Cytosol fraction was loaded onto a DEAE-5PW ion exchange
HPLC column equilibrated with 70 mM Na acetate, 1 mM
EDTA, 5 mM L-mercaptoethanol, 1 mM PMSF, 0.7 Wg/ml leu-
peptin, and 0.7 Wg/ml pepstatin. After washing with a 5 column
volume, bound protein was eluted with a 70^750 mM Na ace-
tate gradient in the same bu¡er. Thirty 1.0 ml fractions were
collected and assayed for PDE activity. The activity measured
in each fraction was corrected for the amount of protein in the
extract loaded on the column.
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3.3. Regulation of cAMP PDE gene expression in
response to TSH
To date, four di¡erent type 4 cAMP PDE genes
have been cloned in mammals. To determine which
PDE genes were expressed in FRTL-5 cells, RNA
was extracted from control cells and cells treated
with TSH, IGF-I, or a combination of the two hor-
mones. The RNA was analyzed by Northern blot
using PDE4A, PDE4B, PDE4C, and PDE4D probes
(Fig. 3A). This analysis demonstrated that all four
cAMP PDEs are expressed in the FRTL-5 cells
under basal conditions. Comparison of the steady-
state mRNA levels of the control and TSH-treated
cells demonstrated signi¢cant increases in PDE4B
and PDE4D mRNA and lesser increases in PDE4C
abundance. PDE4A transcripts were not a¡ected by
the hormonal treatment. IGF-I treatment did not
produce a signi¢cant increase in mRNA or have
any additional e¡ect when combined with TSH.
Fig. 5. Concentration dependence of TSH stimulation of the
cAMP PDE mRNA in FRTL-5 cells. After incubation for 24 h
in the absence of hormones or growth factors, cells were treated
for 24 h in the absence or presence of increasing TSH concen-
tration. At the end of the hormone treatment, cells were har-
vested and the cAMP PDE mRNA levels measured by North-
ern blot analysis as detailed in Section 2. Five micrograms of
poly(A) RNA were loaded on each lane. The experiments
were performed twice independently and a representative blot is
shown.
Fig. 4. Time course of TSH stimulation of the cAMP PDE
mRNA in FRTL-5 cells. After incubation for 24 h in the ab-
sence of hormones or growth factors, cells were treated for the
times indicated in the presence of 1039 M TSH. After incuba-
tion, cells were harvested and the cAMP PDE mRNA levels
were measured by Northern blot analysis as detailed in Section
2. Five micrograms of poly(A) RNA were loaded on each
lane. The experiments were performed three times independently
and a representative blot is shown.
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In agreement with changes observed in PDE activ-
ity, treatment with dibutyryl cAMP or forskolin in-
creased mRNA coding for PDE4B, PDE4C, and
PDE4D (Fig. 3B). Similarly, these two agents had
no signi¢cant e¡ect on the levels of PDE4A
mRNA in these cells. However, TSH increased
PDE4B, PDE4C, and PDE4D mRNAs with a di¡er-
ent time course (Fig. 4). In addition, the concentra-
tion dependence of TSH e¡ects on PDE mRNA was
comparable to observations of PDE activity after 24
h TSH treatment. TSH had half the maximum e¡ect
at a concentration of 10311 M (Fig. 5).
3.4. E¡ects of PDE inhibitors on DNA synthesis
induced by TSH and/or IGF-I
To understand the role of the observed long-term
PDE regulation in FRTL-5 cells, PDE inhibitors
were used to suppress cAMP hydrolysis. To this pur-
pose, cells were incubated with TSH in the absence
or presence of IBMX, a nonspeci¢c PDE inhibitor,
of RO 20-1724, a cAMP PDE-speci¢c inhibitor, or
of cilostamide, a cGMP PDE-speci¢c inhibitor. Ac-
cumulation of cAMP, thymidine incorporation into
DNA, and iodide uptake were measured as parame-
ters of the hormone response (Table 2). As shown in
Table 2, and in agreement with previous reports [23],
both RO 20-1724 and IBMX treatment markedly
potentiated the TSH-dependent cAMP accumulation
in the cells. In addition, both IBMX and RO 20-1724
had a biphasic e¡ect on thymidine incorporation and
these e¡ects could be related to intracellular cAMP
levels. When the PDE inhibitor increased cAMP lev-
els to approx. 30 pmoles/mg protein, they potenti-
ated the thymidine incorporation induced by TSH
or IGF-I. However, when the increased cAMP accu-
mulation exceeded approx. 250 pmoles/mg protein,
an inhibition of thymidine incorporation was invar-
iably observed (Table 2). Maximal inhibitory e¡ects
were observed when TSH and IGF-I were added
together (Table 2). To con¢rm that the inhibitor
treatment had no overall toxic e¡ects, iodide uptake
in response to TSH was measured in the absence or
presence of PDE inhibitors. As shown in Table 2,
both inhibitors potentiated the TSH e¡ects on iodide
uptake by the cells.
3.5. E¡ects of a high concentration of cAMP on cell
cycle progression in G1/S phase
A biphasic e¡ect of RO 20-1724 on thymidine in-
corporation was further con¢rmed by an experiment
where increasing concentrations of TSH were used
(Fig. 6A). At low concentrations of TSH plus IGF-
Table 2
E¡ects of PDE inhibitors on intracellular cAMP contents, thymidine incorporation into DNA and iodine uptake in FRTL-5 cells
No inhibitor RO 20-1724 (1035 M) Cilostamide (1035 M) IBMX (1034 M)
Intracellular cAMP contents (pmole/mg protein)
Control 2.9 þ 0.5 7.0 þ 1.0 2.1 þ 0.1 9.1 þ 0.4
TSH 24.4 þ 5.2 248.7 þ 10.7 37.0 þ 1.1 750.5 þ 34.6
IGF-I 4.0 þ 0.5 10.0 þ 2.0 5.8 þ 1.2 18.3 þ 4.8
TSH+IGF-I 30.3 þ 1.1 450.2 þ 24.0 28.7 þ 0.5 916.3 þ 21.2
Thymidine incorporation into DNA (dpm/4 h/well)
Control 683 þ 13 439 þ 147 546 þ 212 541 þ 18
TSH 1945 þ 430 1459 þ 127 1685 þ 57 365 þ 13
IGF-I 5441 þ 454 8384 þ 1008 3400 þ 263 11 149 þ 796
TSH+IGF-I 27 065 þ 567 8754 þ 1303 17 291 þ 3036 8047 þ 210
Iodine uptake (cpm/2 h/well)
Control 6606 þ 1153 8593 þ 547 7686 þ 849 8824 þ 1034
TSH 15 285 þ 768 24 054 þ 1921 20 767 þ 1369 28 420 þ 1245
IGF-I 7378 þ 554 10 641 þ 408 11 320 þ 1172 13 244 þ 843
TSH+IGF-I 9095 þ 840 7831 þ 984 7816 þ 856 8922 þ 121
Quiescent FRTL-5 cells were treated with no additives, TSH (1039 M), IGF-I (10 ng/ml) or TSH (1039 M)+IGF-I (10 ng/ml) in the
presence or absence of various PDE inhibitors. After 24 h treatment, intracellular cAMP contents, thymidine incorporation into DNA
for the last 4 h, and iodine uptake for an additional 2 h were measured as described in Section 2. Each value is the mean þ S.E.M.
from triplicate wells or dishes.
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I, RO 20-1724 potentiated thymidine incorporation,
whereas RO 20-1724 became inhibitory at high con-
centrations of TSH. At concentrations of TSH
s 1039 M in the presence of IGF-I, we observed
high intracellular cAMP concentrations (Fig. 6B) as
well as inhibitory e¡ects on DNA synthesis. We ob-
tained the same results using IBMX instead of RO
21-1724. As shown in Fig. 7, the e¡ects of RO 20-
1724 were dependent on the concentration used, and
the presence of dibutyryl AMP during TSH and
IGF-I treatment had a similar e¡ect, suggesting
that an increase in cAMP is indeed responsible for
the blockade of thymidine incorporation into DNA.
Speci¢cally, the inhibitory e¡ect of RO 20-1724 on
DNA synthesis induced by TSH plus IGF-I was cor-
related with intracellular cAMP contents (Fig. 7).
The inhibitory e¡ects of RO 20-1724 and IBMX
on thymidine incorporation into DNA were evident
only when they were combined with TSH and IGF-I.
We have shown that the combination treatment of
quiescent FRTL-5 cells with TSH and IGF-I starts
increasing thymidine incorporation at 12^16 h after
treatment and reached its peak with a large potentia-
tion of DNA synthesis at 32^36 h [5]. In Fig. 8, we
added the PDE inhibitors or dibutyryl cAMP at dif-
Fig. 7. E¡ects of PDE inhibitor or cAMP analogue on DNA
synthesis or intracellular cAMP concentrations induced by TSH
and/or IGF-I in FRTL-5 cells. After incubation for 24 h in the
absence of hormones or growth factors, cells were treated for
24 h with or without increasing RO 20-1724 or dibutyryl
cAMP in the presence of TSH (1039 M) and IGF-I (10 ng/ml).
During the last 4 h, [methyl-3H]thymidine incorporation into
DNA was measured as described in Section 2. Each point is
the mean þ S.E.M. of triplicate wells. In addition, at the end of
incubation intracellular cAMP was extracted and measured by
RIA in the case of RO 20-1724 as described in Section 2. Each
point is the mean þ S.E.M. of triplicate wells. The experiments
were performed three times independently and a representative
result is shown.
Fig. 6. Concentration dependence of TSH stimulation of DNA
synthesis and intracellular cAMP concentrations induced by
IGF-I in the presence of a PDE inhibitor. (A) After incubation
for 24 h in the absence of hormones or growth factors, cells
were treated for 24 h with or without RO 20-1724 (1035 M) in
the absence or presence of IGF-I (10 ng/ml) and increasing
TSH concentration. During the last 4 h, [methyl-3H]thymidine
incorporation into DNA was measured as described in Section
2. Each point is the mean þ S.E.M. of triplicate wells. The ex-
periments were performed at least three times independently
and a representative result is shown. (B) At the end of incuba-
tion, intracellular cAMP in cells indicated was extracted and
measured by EIA. Each point is the mean þ S.E.M. of triplicate
wells. The experiments were performed twice independently and
a representative result is shown.
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ferent time points, incubated until 24 h and measured
thymidine incorporation into DNA during the last
4 h. When the PDE inhibitor or dibutyryl cAMP
was added after 12 h, the inhibitory e¡ects gradually
disappeared, suggesting that high levels of intracellu-
lar cAMP inhibit cell cycle progression during G1.
The blockage of thymidine incorporation was com-
pletely reversible upon removal of the PDE inhibi-
tors (data not shown), indicating that the inhibition
is not due to nonspeci¢c toxicity of the drugs used.
This conclusion is further supported by the ¢nding
that neither PDE inhibitor blocked TPA-induced
thymidine incorporation (data not shown).
Fig. 8. Time course of inhibitory e¡ects of PDE inhibitors on
DNA synthesis induced by TSH and IGF-I in FRTL-5 cells.
After incubation for 24 h in the absence of hormones or
growth factors, cells were treated for 24 h with TSH (1039 M)
plus IGF-I (10 ng/ml). Under these conditions, RO 20-1724
(1035 M as ¢nal concentration), IBMX (1034 M as ¢nal con-
centration), or dibutyryl cAMP (1033 M as ¢nal concentration)
was added to the cultures at the indicated time and the cells
were continuously incubated with TSH and IGF-I until 24 h.
During the last 4 h, [methyl-3H]thymidine incorporation into
DNA was measured as described in Section 2. Each point is
the mean þ S.E.M. of triplicate wells. The experiments were per-
formed three times independently and a representative result is
shown.
C
Fig. 9. E¡ects of PDE inhibitors on changes of G1 cyclin and
CDK, CDK inhibitor and CDK activities induced by TSH and/
or IGF-I in FRTL-5 cells. (A) After incubation for 24 h in the
absence of hormones or growth factors, cells were treated for
24 h with or without RO 20-1724 (1035 M), or IBMX (1034
M), or dibutyryl cAMP (1033 M) in the absence or presence of
TSH (1039 M) and IGF-I (10 ng/ml). The amounts of cyclin
D1, cyclin E, CDK2, CDK4, p27Kip1, and phosphoRb (S807/
811) were analyzed by immunoblotting using each antibody as
described in Section 2. In addition, histone H1 kinase activity
in the immunoprecipitates by anti-cyclin E was measured as de-
scribed in Section 2. The experiments were performed three
times independently and a representative result is shown. (B)
After incubation for 24 h in the absence of hormones or
growth factors, cells were treated for various times with or
without RO 20-1724 (1035 M) in the absence or presence of
TSH (1039 M) and IGF-I (10 ng/ml). The amounts of cyclin
D1, cyclin E and p27Kip1 were analyzed by immunoblotting us-
ing each antibody as described in Section 2. We performed
these experiments at least three times and a representative blot
is shown.
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3.6. E¡ects of PDE inhibitors on changes in G1
cyclins, cyclin-dependent kinase (CDK), CDK
inhibitor (CKI) and CDK activity induced by
TSH and/or IGF-I
Lastly, we analyzed the e¡ects of PDE inhibitors
or dibutyryl cAMP on the changes in G1 cyclins,
CDKs, and CKI induced by TSH and/or IGF-I
(Fig. 9A). TSH or IGF-I acting individually induced
cyclin D1 and cyclin E as others reported [24,25],
and the combination of TSH and IGF-I caused addi-
tional increases in their amounts. Combination of
TSH and IGF-I also increased the amounts of
CDK2 as well as CDK4. TSH treatment has been
shown to decrease p27Kip1, one of the CKIs that is an
essential participant in the regulation of cell cycle
progression [25]. In our system, combination of treat-
ment with TSH and IGF-I clearly decreased p27Kip1.
Under these conditions, the presence of RO 20-1724
or IBMX, or dibutyryl cAMP at a high concentra-
tion completely abolished a TSH and IGF-I-depen-
dent increase in cyclin D1; however, it did not a¡ect
the changes of amounts of cyclin E and p27Kip.
These inhibitory e¡ects of RO 20-1724 on cyclin
D1 were observed after 12 h incubation with TSH
and IGF-I (Fig. 9B), but this inhibitor did not a¡ect
the kinetics of cyclin E and p27Kip1 prominently. We
obtained the same results using IBMX or dibutyryl
cAMP instead of RO 21-1724. Because cyclin D-as-
sociated CDKs have been reported to phosphorylate
retinoblastoma protein (Rb) at Ser-807 and Ser-811
[26], we measured Rb phosphorylation at Ser-810/
811 by immunoblotting using a speci¢c antibody.
In addition, cyclin E-associated CDK activity was
measured as histone H1 phosphorylation activity in
the immunoprecipitates by anti-cyclin E antibody.
Both cyclin D-associated CDK activity and cyclin
E-associated CDK activity induced by TSH and
IGF-I was inhibited by the presence of PDE inhib-
itors or dibutyryl cAMP (Fig. 9C).
4. Discussion
The data described demonstrate that long-term
TSH stimulation increases the PDE activity of the
FRTL-5 thyroid cell line. The TSH induction of
the PDE is mediated by an increase in intracellular
cAMP concentration and coincides with the stimula-
tion of mitosis by TSH.
Whereas all of the four known cAMP PDE genes
are expressed in FRTL-5 cells, the increase in PDE
activity after TSH stimulation is due to increased
PDE4B and PDE4D and to a lesser extent PDE4C
induction (Fig. 3). In none of the experiments per-
formed, was the mRNA encoding PDE4A a¡ected
by either TSH or cAMP-generating agents, although
in other cell lines cAMP has been reported to in-
crease PDE4A mRNA [27^29]. The response of the
various PDE mRNAs to cAMP di¡ered in their time
courses (Fig. 4). This suggests that the regulation of
each PDE may be di¡erent as might be expected
from the presence of multiple cAMP PDE genes in
rat and human.
In FRTL-5 cells, TSH stimulates PDE activity in a
biphasic fashion. TSH produces a transient increase
in intracellular cAMP concentration and at the same
time an increase in PDE activity. As previously re-
ported, the early e¡ects of TSH are due to rapid
phosphorylation and activation of a PDE4D form
in FRTL-5 cells [12,21]. This rapid activation is fol-
lowed by a delayed increase in PDE activity, which is
dependent on RNA and protein synthesis. This is
similar to observations in other endocrine systems
such as the Sertoli cells, where an increase in
cAMP PDE plays a major role in producing long-
term desensitization to FSH [30]. The increases in
PDE activity in response to long-term cAMP treat-
ment suggest that intracellular cAMP regulates its
own degradation in thyroid cells.
The role of cAMP in the regulation of mitosis has
been debated because both stimulatory and inhibi-
tory e¡ects have been reported [7,8]. Along the
same line, an increase in cAMP has both stimulatory
and inhibitory e¡ects on thymidine incorporation in
FRTL-5 cells. There are precedents for a biphasic
e¡ect of cAMP. In BALB/c-3T3 ¢broblasts, cAMP
has been shown to either stimulate or inhibit DNA
synthesis depending on its concentration [9,10]. In
these cells, elevation of intracellular cAMP by the
PDE inhibitor IBMX potentiates induction of com-
petence in response to cholera toxin, and also inhib-
ited serum stimulation of DNA synthesis by revers-
ibly blocking the transit through G1 phase at a point
6 h prior to initiation of DNA synthesis. Our data
show that the e¡ect of PDE inhibitors on DNA syn-
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thesis induced by TSH and IGF-I is biphasic in
FRTL-5 cells (Fig. 6). They potentiate the TSH
and IGF e¡ects on DNA synthesis when only a small
increase in cAMP is induced in these cells. At a high
concentration of TSH, when cAMP levels are high,
inhibition of DNA synthesis becomes the predomi-
nant e¡ect (Fig. 6). Under the conditions where
DNA synthesis was inhibited by high cAMP concen-
trations, we observed an inverse relation between
cAMP levels and DNA synthesis. Consistent with
this view is the observation that the cAMP analogue
dibutyryl cAMP is either stimulatory or inhibitory,
depending on the concentration of intracellular
cAMP. Villone et al. also reported that treatment
of thyroid cells with PDE inhibitors induced persis-
tent levels of cAMP and blocks cAMP-dependent
cell proliferation [31]. All these observations clearly
indicated that sustained and steady high levels of
intracellular cAMP inhibit cell cycle progression
from G1 to S phase. Similarly in human lymphocytes
or rat thymic cells, it has been shown that lectins
produce a large increase in PDE activity at the
same time that they stimulate thymidine incorpora-
tion into DNA [32^34]. In addition, several di¡erent
PDE inhibitors block the mitogenic response to lec-
tins [32,35]. Thus, we propose that long-term cAMP
PDE induction plays an important role in cell cycle
progression by regulating cAMP concentration.
The mechanisms by which sustained cAMP levels
arrest the cell cycle during G1 phase is still unclear.
In the present study, we found that this inhibitory
e¡ect is reversible and the arresting point may be at
4^8 h before entering S phase (data not shown). It is
now known that the cyclin/CDK/CDK inhibitor sys-
tem plays an important role in regulating progression
through the G1 phase of the cell cycle. We and others
have shown that cAMP treatment increases G1 cy-
clins, and both cAMP and IGF-I decrease p27Kip1.
These changes are followed by activation of CDK
and RB phosphorylation in FRTL-5 cells
[24,36,37]. In thyroid cells as well as other cell lines,
CDK activation and Rb phosphorylation occurred at
the border of G1^S phase transition in response to
cAMP stimulation (see for a review [38^41]).
We now show that PDE inhibitors or dibutyryl
cAMP at a high concentration abolish the increase
in cyclin D1 produced by TSH and IGF-I treatments
in this cell line, resulting in depression of cyclin D-
associated CDK activation induced by TSH and
IGF-I (Fig. 9). Feliciello et al. reported that addi-
tional upregulation of the cAMP signaling pathway
inhibited the subsequent decay of p27Kip1 and de-
layed cell cycle progression to the S phase induced
by TSH and insulin in one clone of FRTL-5 cells
[42]. However, in our systems PDE inhibitors in-
creased p27Kip to a small extent only at 3 h after
stimulation with TSH and IGF-I, but did not a¡ect
a decrease in p27Kip1 later, suggesting that cyclin D-
associated CDK activity was depressed mainly by a
decrease in cyclin D1 levels. Although we con¢rmed
a decrease in p27Kip1 after treatment with TSH in the
absence of IGF-I (data not shown) as others re-
ported [25], the changes in p27Kip1 were much greater
in the case of TSH and IGF-I treatment. Under these
conditions, we found that TSH and IGF-I-dependent
activation of cyclin E-associated CDK activities was
also abolished by the addition of PDE inhibitors or
cAMP analogue, even though the levels of cyclin E
and CDK2 were not changed (Fig. 9). Carneiro et al.
reported that in FRTL-5 cells TGF-L1 treatment re-
duced the activity of cyclin E-CDK2 complexes by
increasing association of p27Kip1 with these com-
plexes [43]. Treatment with high cAMP may cause
a similar response and this mechanism could also be
important to control the cell cycle by cAMP. On the
other hand, cAMP stimulation increased p27Kip1 and
high sustained levels of cAMP are required for G1^S
transition through di¡erent mechanisms in a dog
thyroid system [44,45]. The di¡erence of the cAMP
e¡ects between FRTL-5 and other thyroid cells needs
to be elucidated.
Our data support the concept that TSH produces
changes both at the level of the adenylate cyclase,
and at the level of PDEs. It is likely that both the
magnitude and the duration of the increase in cyclic
nucleotides are critical for an e⁄cient transition
through the G1^S phase, and the regulation of the
cAMP PDE activity probably contributes to this
¢ne-tuning.
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